Voyager Therapeutics names Robin Swartz president, expected to succeed CEO Sandrock

VYGR•2026-11-05

Voyager Therapeutics appointed Robin Swartz president in October 2026 as part of a planned leadership transition. Swartz is expected to succeed Alfred W. Sandrock, Jr. as CEO.

1. Planned leadership transition

Voyager Therapeutics appointed Robin Swartz president in October 2026. Swartz is expected to succeed Alfred W. Sandrock, Jr. as CEO.

Voyager Therapeutics names Robin Swartz president, expected to succeed CEO Sandrock

1. Planned leadership transition

Related News

Century Aluminum Q3 2026 attributable net income rises 21% quarter-on-quarter to $302.6 million

Rithm Capital CFO Nicola Santoro Jr. reports sale of common shares worth $951,000

Horizon Technology Finance Q3 net investment income per share falls

Akamai Q3 operating income drops 35% to $109 million; revenue rises 6% to $1.12 billion

LB Pharmaceuticals Q3 loss widens on higher expenses